Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Industry News
Share your love
ENTOD Pharma Introduces New Eye Drop Preservative System
Mumbai-based ENTOD Pharmaceuticals has unveiled a novel advancement in ophthalmic care with the introduction of EyeBS, a new eye drop preservative system. EyeBS is specifically designed to supplant traditional detergent-based preservatives such as Benzalkonium Chloride (BAK) and Polyquaternium-1, offering a…
Study Highlights Significant Drug Waste from SUCD for Eye Drops
A recent report published online in Ophthalmology reveals alarming levels of drug wastage and associated costs due to self-imposed use cessation dates (SUCD) for multiuse eye drop bottles. John M. Tan and colleagues from the Icahn School of Medicine at…
FDA Clears Enhanced SPECTRALIS® OCTA Module by Heidelberg
Heidelberg Engineering announced the FDA clearance of its upgraded SPECTRALIS® OCTA Module featuring SHIFT technology. This advancement promises to significantly reduce acquisition time by 50%, marking a pivotal development in clinical efficiency and diagnostic precision within ophthalmology. Enhancing Clinical Utility…
Sydnexis Appoints Perry J. Sternberg as CEO
Sydnexis, Inc., a pioneering biopharmaceutical company dedicated to addressing pediatric myopia progression, has appointed Perry J. Sternberg as its Chief Executive Officer and as a member of its Board of Directors. Sternberg, a seasoned pharmaceutical and biotech executive with over…
Genentech Reintroduces Susvimo Ocular Implant for Wet AMD
Genentech announced the reintroduction of Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant, aimed at treating wet age-related macular degeneration (AMD). This decision follows the FDA’s approval of a post-approval supplement to the Biologics License Application, which…
Outlook Therapeutics Receives UK Approval of Lytenava for AMD
Outlook Therapeutics announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Lytenava (bevacizumab gamma) for the treatment of wet age-related macular degeneration (AMD) in the UK. Lytenava is the first and only authorized…
Glaukos Activates CMS J-Code for iDose TR
Glaukos Corporation has confirmed the activation of the CMS Healthcare Common Procedure Coding System’s J-code—J7355—for its iDose TR product. This development marks a significant milestone in enhancing patient access and streamlining coverage and payment processes for the innovative treatment, according…
FDA Greenlights Formycon and Klinge’s Biosimilar to Eylea
Formycon AG and its licensing partner Klinge Biopharma GmbH announced the U.S. Food and Drug Administration’s (FDA) approval of FYB203/AHZANTIVE®, a biosimilar to Eylea®. FYB203/AHZANTIVE® has been approved by the FDA for the treatment of patients with Age-Related Neovascular (wet)…
Study Suggests Novel Treatment Approach for Wet AMD
A recent study conducted on mice has provided promising insights into a potential alternative treatment for the “wet” version of age-related macular degeneration (AMD). Researchers identified an enzyme, telomerase, which plays a critical role in the abnormal blood vessel growth…
Researchers Use Novel Phototherapy to Target Ocular Melanoma
Scientists from the Optics and Photonics Research Center (CePOF) in Brazil, along with collaborators from the University of Toronto and Princess Margaret Cancer Center in Canada, have achieved a significant breakthrough in cancer treatment. Their study, published in Proceedings of…